AbbVie announced a $1.4B investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.
This is AbbVie's first major investment in North Carolina. The AbbVie Durham campus, located near Research Triangle Park, was selected for the strength of the region's local workforce and its ability to support future expansion. Construction will begin this year, with completion expected by the end of 2028.
"Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina."
Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators and laboratory technicians. The project will also support the local economy by generating more than 2,000 construction jobs during campus development.
This project is part of the company's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade. The first phase of construction will include small volume parenteral (SVP) drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities with room to support AbbVie's growing pipeline.
"We welcome AbbVie's major investment to North Carolina," said Governor Josh Stein. "When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!